Patent US6506148B2 genuinely exists: filed on 1 June 2001 and granted on 14 January 2003 by the US patent office (USPTO), it is titled, literally, "Nervous system manipulation by electromagnetic fields from monitors". But a granted patent proves the novelty of a method — not that it works, nor that it has ever been deployed. That distinction is everything.
DOCUMENTED FACT. The document is authentic and verifiable in two independent official registers (USPTO and, on the European side, Espacenet). Publication number US6506148B2, application 09/872,528, anticipated expiration 1 June 2021: the patent is now expired and in the public domain. None of this is interpretation — it is stated plainly in the official record.
The abstract is precise: "physiological effects have been observed in a human subject" in response to weak electromagnetic fields pulsed near ½ Hz or 2.4 Hz, capable of exciting what the inventor calls a "sensory resonance". The patent asserts that many computer monitors and TV tubes, when displaying pulsed images, emit fields strong enough to cause it. The claimed idea: modulate a screen's image, possibly subliminally, to act on the nervous system of a nearby person.
The effects described are crude physiological responses, not "mind control": eyelid ptosis, relaxation, drowsiness, pressure at the brow, coloured patterns with eyes closed, a tonic smile, stomach tension, loose stool, sexual excitement — varying by exact frequency and skin area. That is the patent's real content, often far from the sensational summaries.
DOCUMENTED FACT. The inventor is Hendricus G. Loos, a private individual. The registered assignee is "Individual": neither the CIA, nor DARPA, nor any government agency appears on the title. This dismantles the most common online claim that it is a "secret government patent". A patent is public by definition, and this one belonged to a private person.
CORRELATION. Loos filed more than one title: the patent itself cites a family of about a dozen related Loos patents on "sensory resonance" (e.g. US5782874, US5899922, US6081744, US6167304, US5935054, US6238333, US6017302). This traces a persistent private research line by one individual — not the footprint of a coordinated institutional program.
This is the core misunderstanding. The USPTO examines an application on three criteria: novelty, non-obviousness and utility. "Utility" is a very low bar — the invention must have a credible use, not demonstrated efficacy. A patent is never scientific validation: no peer review, no reproducibility requirement, no proof the device works reliably in the real world.
Concretely, US6506148B2 establishes none of the following: that consumer screens actually manipulate viewers today; that the method was deployed at scale; that "a human subject" means a controlled study (the reported observations are the inventor's own, with no independent replication cited); nor that it involves thought-reading or behavioural control. A patent documents a claim, not a verified reality.
HYPOTHESIS (interpretation). The explicit title — "nervous system manipulation by electromagnetic fields" — on an official US document is enough to fuel concern. The classic slippage is to treat the patent's existence as proof of deployment. Yet the real story is more sober and more useful: a private inventor patented a method that is plausible on paper, never independently validated, now in the public domain. Vigilance toward neuro-active technologies remains legitimate — but it is better served by what the documents actually establish.
Is patent US6506148B2 real? Yes. It is granted, public and verifiable in the USPTO and Espacenet registers. It expired on 1 June 2021.
Does it prove TVs manipulate our brains? No. A patent attests the novelty of a claimed method, not its efficacy, deployment or scientific validation.
Was it filed by the CIA or DARPA? No. The registered assignee is a private individual, Hendricus G. Loos; no government agency appears.
What did "human subject" mean in the patent? The effects are observations reported by the inventor, without a controlled study or cited independent replication — not clinical proof.
Yes. It is granted, public and verifiable in the USPTO and Espacenet registers. It expired on 1 June 2021.
No. A patent attests the novelty of a claimed method, not its efficacy, deployment or scientific validation.
No. The registered assignee is a private individual, Hendricus G. Loos; no government agency appears.
The effects are observations reported by the inventor, without a controlled study or cited independent replication — not clinical proof.
Dossier : Guerre cognitive & neuro-armes
MINI13: MK-Ultra 2.0 — Les Neuro-Armes
Accueil · Collection · Journal · Dossiers · Sources